AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
Daratumumab
4 registrations across 3 African markets— 2 active
Markets with Daratumumab
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| DARZALEX 1 800 mg SOLUTION FOR INJECTION | 🇿🇦South Africa | Janssen Pharmaceutica (Pty) Ltd | active | Mar 2029 |
| DARZALEX Solution à diluer pour perfusion / 20mg/ml | 🇹🇳Tunisia | Janssen-Cilag International N.V | expired | Oct 2021 |
| DARZALEX Solution à diluer pour perfusion / 20mg/ml | 🇹🇳Tunisia | Janssen-Cilag International N.V | expired | Oct 2021 |
| IMFINZI 500 MG/10 ML Solution for Infusion | 🇹🇿Tanzania | AstraZeneca UK Limited | active | — |
Daratumumab in Africa — Regulatory Overview
Daratumumab is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Tanzania, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 2 (50%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.